Sign in
Not yet taking people in United StatesNo phase

Testing how genes affect blood pressure response to salt intake and saline infusion

Tests low-salt diet, high-salt diet, and saline infusion in adults with high blood pressure.

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, United StatesSee the site
Trial code
Registry title
Genetic Architecture of Natriuretic Peptides and Blood Pressure Response
Status
Not yet recruiting
People taking part
200 people, planned
Started
1 Sept 2026
Expected to end
1 Dec 2030
Type of study
Interventional, 2 groups
Treatments tested
  • Low Salt Diet
  • High Salt Diet
  • Saline Infusion
Record updated
10 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with stage I or II high blood pressure who agree to give genetic material and follow the study plan.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Stage I/II hypertension (systolic blood pressure 130-159 and diastolic 80-99 mm Hg).
Earlier treatment
People taking 2 or more blood pressure medicines at screening cannot join.

Main reasons for not taking part

  • Body mass index (BMI) above 45 kg/m2
  • Uncontrolled high blood pressure (160 or higher systolic and/or 100 or higher diastolic)
  • Major heart or brain disease, such as heart attack, angina, arrhythmia, heart failure, stroke, TIA or seizure
  • Kidney disease, or insulin-requiring diabetes
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Age more than or equal to 18 years
  • Consenting to collection of genetic material and willing to adhere to study protocol
  • Stage I/II Hypertension (Systolic blood pressure: 130-159 and Diastolic blood pressure: 80-99 mm Hg)

Who cannot take part

  • If taking more than or equal to 2 blood pressure medications at the time of screening
  • History of uncontrolled hypertension (i.e., Systolic blood pressure more than or equal to 160 mmHg and/or Diastolic blood pressure more than or equal to 100 mmHg)
  • Present or past history of major cardiovascular disease including myocardial infarction, angina, cardiac arrhythmia, heart failure, stroke, transient ischemic attack, or seizure
  • History of kidney disease
  • History of insulin requiring diabetes
  • Estimated glomerular filtration rate less than 60ml/min/1.73 m2, albumin creatinine ratio more than or equal to 30 mg/g
  • Hepatic transaminase levels more than 3 times the upper limit of normal
  • Anemia (men, Hb less than 13 g/dL; women, Hb less than 12 g/dL)
  • Body mass index (BMI) more than 45 kg/m2
  • Systolic blood pressure more than 180 and/or Diastolic blood pressure more than or equal to 120 mmHg at any point in the study
  • Pregnant or breastfeeding individuals

Where in United States

  • University of Alabama at BirminghamBirmingham, United StatesContact: Nehal Vekariya, MSNot yet recruiting

About the trial

What the trial wants to find out

Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.

The 2 groups in the trial

  • High Natriuretic Peptide Polygenic ScoreTreatment being tested

    Active Comparator: High NP PGS Group

    Treatment: Low Salt Diet, High Salt Diet, and Saline Infusion

  • Low Natriuretic Peptide Polygenic ScoreTreatment being tested

    Experimental: Low NP PGS Group

    Treatment: Low Salt Diet, High Salt Diet, and Saline Infusion

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Genetic Architecture of Natriuretic Peptides and Blood Pressure Response
Plain-language title
Testing how genes affect blood pressure response to salt intake and saline infusionGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
10 March 2026